Estelle Leclerc

Prof. Estelle Leclerc

North Dakota State University (NDSU), Fargo, ND, USA.
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2010 in Cardiovascular Psychiatry and Neurology
Verified
Journal Article
Open access
PDF file
ELEstelle Leclerc
Estelle Leclerc
ESEmmanuel Sturchler
Emmanuel Sturchler
SVStefan W. Vetter
Stefan W. Vetter
Increasing evidence suggests that the small EF-hand calcium-binding protein S100B plays an important role in Alzheimer's disease. Among other evidences are the increased levels of both S100B and its receptor, the Receptor for Advanced Glycation Endproducts (RAGEs) in the AD diseased brain. The regulation of RAGE signaling by S100B is complex and probably involves other ligands including the amyloid beta peptide (A), the Advanced Glycation Endproducts (AGEs), or transtheyretin. In this paper we discuss the current literature regarding the role of S100B/RAGE activation in Alzheimer's disease.

1 December 2015 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
ELEstelle Leclerc
Estelle Leclerc
SVStefan W. Vetter
Stefan W. Vetter

4 December 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
KCKaylen Cross
Kaylen Cross
SVStefan W. Vetter
Stefan W. Vetter
YAYousuf Alam
Yousuf Alam
MHMd Zahidul Hasan
Md Zahidul Hasan
ANAnupom Deb Nath
Anupom Deb Nath
ELEstelle Leclerc
Estelle Leclerc
Since its discovery in 1992, the receptor for advanced glycation end products (RAGE) has emerged as a key receptor in many pathological conditions, especially in inflammatory conditions. RAGE is expressed by most, if not all, immune cells and can be activated by many ligands. One characteristic of RAGE is that its ligands are structurally very diverse and belong to different classes of molecules, making RAGE a promiscuous receptor. Many of RAGE ligands are damaged associated molecular patterns (DAMPs) that are released by cells under inflammatory conditions. Although RAGE has been at the center of a lot of research in the past three decades, a clear understanding of the mechanisms of RAGE activation by its ligands is still missing. In this review, we summarize the current knowledge of the role of RAGE and its ligands in inflammation.

1 January 2011 in Frontiers in Bioscience-Scholar
Verified
Journal Article
Closed access
ELEstelle Leclerc
Estelle Leclerc
CHClaus W Heizmann
Claus W Heizmann
The Receptor for Advanced Glycation Endproducts (RAGE) is a multiligand receptor involved in a large number of human disorders. Identified first as the receptor for the Advanced Glycation Endproducts (AGEs), RAGE has emerged in recent years as a major receptor for many members of the S100 calcium and zinc binding protein family. The interaction with and the signaling triggered by several S100 proteins such as S100B and S100A12 have been studied in details and have shown concentration and cell type dependent signaling cascades. The S100 protein family consists of more than 20 members which present high amino-acid sequence and structural similarities. These small EF-hand calcium binding proteins interact with a large number of protein targets and are almost all been shown to be involved in cancer. In this review we discuss the recent knowledge about the role of S100 proteins and RAGE in human disorders.

Verified
Journal Article
Open access
PDF file
STSakshi Taneja
Sakshi Taneja
SVStefan W. Vetter
Stefan W. Vetter
ELEstelle Leclerc
Estelle Leclerc
Hypoxia is characterized by an inadequate supply of oxygen to tissues, and hypoxic regions are commonly found in solid tumors. The cellular response to hypoxic conditions is mediated through the activation of hypoxia-inducible factors (HIFs) that control the expression of a large number of target genes. Recent studies have shown that the receptor for advanced glycation end products (RAGE) participates in hypoxia-dependent cellular adaptation. We review recent evidence on the role of RAGE signaling in tumor biology under hypoxic conditions.

Verified
Journal Article
Open access
PDF file
PSPriyanka Swami
Priyanka Swami
STSwetha Thiyagarajan
Swetha Thiyagarajan
AVArianna Vidger
Arianna Vidger
VIVenkata S. K. Indurthi
Venkata S. K. Indurthi
SVStefan W. Vetter
Stefan W. Vetter
ELEstelle Leclerc
Estelle Leclerc
The receptor for advanced glycation end products (RAGE) contributes to many cellular aspects of pancreatic cancer including cell proliferation, migration, and survival. Studies have shown that RAGE activation by its ligands promotes pancreatic tumor growth by stimulating both cell proliferation and migration. In this study, we investigated the effect of RAGE up-regulation on the proliferation and migration of the human pancreatic cancer Panc-1 cell-line. We show that moderate overexpression of RAGE in Panc-1 cells results in increased cell proliferation, but decreased cell migration. The observed cellular changes were confirmed to be RAGE-specific and reversible by using RAGE-specific siRNAs and the small molecule RAGE inhibitor FPS-ZM1. At the molecular level, we show that RAGE up-regulation was associated with decreased activity of FAK, Akt, Erk1/2, and NF-κB signaling pathways and greatly reduced levels of α2 and β1 integrin expression, which is in agreement with the observed decreases in cell migration. We also demonstrate that RAGE up-regulation changes the expression of key molecular markers of epithelial-to-mesenchymal transition (EMT). Our results suggest that in the absence of stimulation by external ligands, RAGE up-regulation can differently modulate cell proliferation and migration in pancreatic cancer cells and regulates partly EMT.